Letter to the editor: Organ shortage and pediatric liver transplantation: David against Goliath…
Jean Ville de Goyet, Ulrich Baumann, Vincent Karam, Henkjan J. Verkade – 13 January 2022
Graft Fibrosis Over 10 to 15 Years in Pediatric Liver Transplant Recipients: Multicenter Study of Paired, Longitudinal Surveillance Biopsies
Emily R. Perito, Elodie Persyn, John Bucuvalas, Mercedes Martinez, Saeed Mohammad, James E. Squires, Anthony J. Demetris, Sandy Feng – 12 January 2022 – Previous single‐center, cross‐sectional studies have reported a steep increase in the prevalence and severity of fibrosis through 10 to 15 years after pediatric liver transplantation. We report a multicenter study of paired surveillance biopsies in a contemporary cohort.
Letter to the editor: Liver splitting during ex‐situ perfusion: Do not count your chickens before they are hatched…
Jean de Ville de Goyet, Olivier Boillot – 12 January 2022
Letter to the editor: Is there a place for machine perfusion strategies in pediatric liver transplantation?
Guillaume Rossignol, Xavier Muller, Kayvan Mohkam, Remi Dubois, Jean‐Yves Mabrut – 12 January 2022
Combining immune checkpoint inhibitors with immunomodulators: Lessons from different metastatic sites
Einat Cinnamon, Eli Pikarsky – 12 January 2022
The digital transformation of hepatology: The patient is logged in
Tiffany Wu, Douglas A. Simonetto, John D. Halamka, Vijay H. Shah – 12 January 2022 – The rise in innovative digital health technologies has led a paradigm shift in health care toward personalized, patient‐centric medicine that is reaching beyond traditional brick‐and‐mortar facilities into patients’ homes and everyday lives. Digital solutions can monitor and detect early changes in physiological data, predict disease progression and health‐related outcomes based on individual risk factors, and manage disease intervention with a range of accessible telemedicine and mobile health options.
Postvaccination COVID‐19 infection is associated with reduced mortality in patients with cirrhosis
Binu V. John, Yangyang Deng, Kaley B. Schwartz, Tamar H. Taddei, David E. Kaplan, Paul Martin, Hann‐Hsiang Chao, Bassam Dahman – 11 January 2022
T cells: Friends and foes in NASH pathogenesis and hepatocarcinogenesis
Pierluigi Ramadori, Shing Kam, Mathias Heikenwalder – 11 January 2022 – In association with the pandemic spreading of obesity and metabolic syndrome, the prevalence of NAFLD‐related HCC is increasing almost exponentially. In recent years, many of the underlining multifactorial causes of NAFLD have been identified, and the cellular mechanisms sustaining disease development have been dissected up to the single‐cell level.
Risk Factors for Posttransplantation Mortality in Recipients With Grade 3 Acute‐on‐Chronic Liver Failure: Analysis of a North American Consortium
Vinay Sundaram, Sarvanand Patel, Kirti Shetty, Christina C. Lindenmeyer, Robert S. Rahimi, Gianina Flocco, Atef Al‐Attar, Constantine J. Karvellas, Suryanarayana Challa, Harapriya Maddur, Janice H. Jou, Michael Kriss, Lance L. Stein, Alex H. Xiao, Ross H. Vyhmeister, Ellen W. Green, Braidie Campbell, William Cranford, Nadim Mahmud, Brett E.
LiverLearning®: 2022 Webinar: HBV DNA Integration: Mechanisms, Pathogenesis and Clinical Relevance in Liver Disease Progression and Functional Cure
The goal of this webinar is to review mechanisms of HBV DNA integration in the context of potential clinical relevance including HCC, clinical monitoring, treatment and emerging therapeutics towards a functional cure. Some questions to be explored re: HBV DNA integration in this webinar: What is it? How/when does it happen? What is its potential impact in liver disease pathogenesis and clinical outcome (e.g. HCC)? What are potential impact of HBV DNA integration on timing of treatment initiation, clinical monitoring and novel therapeutic development?Stefan F.